Express News | Dyne Therapeutics Announces New Clinical Data From Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

ReutersSep 3 06:30 ET

Chardan Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50

Moomoo News23:31 ET · Ratings

Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics

TipRanks22:35 ET · Ratings

Small U.S. Stocks Decrease; Dyne Therapeutics Takes Biggest Hit

Dow Jones16:20 ET

Dyne Therapeutics Analyst Ratings

Benzinga13:50 ET · Ratings

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

Yahoo Finance12:37 ET